Many groundbreaking scientific discoveries never reach patients because they fail to attract capital or secure a commercial partnership. This "translation death" highlights that business development, not just R&D, is a critical bottleneck in delivering therapies to patients.
MediciNova's drug MN-166 (ibudilast) has a distinct mechanism that doesn't target the motor neuron itself. Instead, it dials down neuroinflammation and over-activated glial cells. This creates a less toxic, more protective environment, improving the neuron's chances of survival.
By outsourcing development and maintaining a core team of only nine people, MediciNova advances a late-stage CNS asset with a $12-13 million annual burn—a figure many biotechs spend quarterly. This ultra-lean model minimizes shareholder dilution while pursuing a high-value program.
Pharma's renewed interest in neuroscience is not for early-stage discovery. They are underwriting late-stage, de-risked assets with human proof-of-concept, understood mechanisms, and biomarker data. This strategy allows them to buy optionality on validated programs while avoiding the high cost of early failures.
Since the failure and market withdrawal of Relyvrio, regulators now require a higher standard of evidence for ALS drugs. A marginal signal is insufficient; companies must show a clear, coherent story across function, survival, and biomarkers to gain approval and convince payers.
While a pivotal trial proves causation for regulators, an expanded access study plays a complementary role. It adds 'texture' by gathering real-world safety and biomarker data in a broader patient population, reinforcing the regulatory and commercial story without substituting for controlled evidence.